Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease by �떊�꽦�옱
Clinical Characteristics, Treatment Outcomes, and Resistance
Mutations Associated with Macrolide-Resistant Mycobacterium avium
Complex Lung Disease
Seong Mi Moon,a Hye Yun Park,a Su-Young Kim,a Byung Woo Jhun,a Hyun Lee,a Kyeongman Jeon,a Dae Hun Kim,a Hee Jae Huh,b
Chang-Seok Ki,b Nam Yong Lee,b Hong Kwan Kim,c Yong Soo Choi,c Jhingook Kim,c Seung-Heon Lee,d Chang Ki Kim,d
Sung Jae Shin,e Charles L. Daley,f Won-Jung Koha
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Koreaa;
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Koreab; Department of Thoracic
Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Koreac; Korean Institute of Tuberculosis, Cheongju, South Koread;
Department of Microbiology, Yonsei University College of Medicine, Seoul, South Koreae; Division of Mycobacterial and Respiratory Infections, Department of Medicine,
National Jewish Health, Denver, Colorado, USAf
Macrolide antibiotics are key components of the multidrug treatment regimen for treating lung disease (LD) due toMycobacte-
rium avium complex (MAC). Despite the emergence of macrolide resistance, limited data are available on macrolide-resistant
MAC-LD. This study evaluated the clinical features and treatment outcomes of patients with macrolide-resistant MAC-LD and
the molecular characteristics of the macrolide-resistant isolates. A retrospective review of the medical records of 34 patients with
macrolide-resistant MAC-LD who were diagnosed between January 2002 and December 2014 was performed, along with genetic
analysis of 28 clinical isolates. Nineteen (56%) patients had the fibrocavitary form of MAC-LD, and 15 (44%) had the nodular
bronchiectatic form.M. intracellularewas the etiologic organism in 21 (62%) patients. Approximately two-thirds (22/34 [65%])
of the patients had been treated with currently recommendedmultidrug regimens that includedmacrolide, ethambutol, and
rifamycin prior to the emergence of macrolide resistance, and none had been treated with macrolide monotherapy. The median
duration of treatment after the detection of macrolide resistance was 23.0 months (interquartile range, 16.8 to 45.3 months).
Treatment outcomes were poor after the development of macrolide resistance, with favorable treatment outcomes achieved in
only five (15%) patients, including two patients who underwent surgical resection. One-, 3-, and 5-year mortality rates were 9,
24, and 47%, respectively. Molecular analysis of 28 clinical isolates revealed that 96% (27/28) had point mutations at position
2058 or 2059 of the 23S rRNA gene. Our analyses indicate that more effective therapy is needed to treat macrolide-resistant
MAC-LD and prevent its development.
The Mycobacterium avium complex (MAC) predominantlyconsists of M. avium and M. intracellulare and in many coun-
tries has been reported as the most common etiology of lung dis-
ease caused by nontuberculous mycobacteria (NTM) (1, 2).
Newer macrolides, such as clarithromycin and azithromycin, are
cornerstones in the antibiotic treatment of MAC lung disease
(MAC-LD) (3–7), and macrolides, and perhaps amikacin, are the
only drugs with a consistent correlation between in vitro suscep-
tibility results and clinical response in MAC-LD (8–12). There-
fore, a macrolide-based multidrug regimen that consists of a mac-
rolide, a rifamycin (rifampin or rifabutin), and ethambutol, with
or without the initial use of streptomycin or amikacin, is the cur-
rently recommended standard therapy for patients with MAC-LD
(13).
Because macrolides are key drugs for the treatment of MAC-
LD, the development of macrolide resistance indicates a poor
treatment outcome and increased mortality (14, 15). However,
there have been only two previous studies evaluating the risk fac-
tors, clinical characteristics, and treatment outcomes of macro-
lide-resistant MAC-LD, and the results are inconsistent, especially
regarding the risk factors and optimal treatment modalities (14,
15). The aim of this study was to evaluate the clinical features and
treatment outcomes of patients with macrolide-resistant MAC-
LD, as well as the molecular characteristics of macrolide-resistant
MAC isolates.
MATERIALS AND METHODS
Study populations. The medical records of all patients with macrolide-
resistant MAC-LD identified from the NTM Registry of Samsung Medical
Center (a 1,979-bed referral hospital in Seoul, South Korea) from January
2002 to December 2014 were reviewed. All the patients fulfilled the diag-
nostic criteria of NTM lung disease (13). This retrospective study was
approved by the Institutional Review Board (IRB) of Samsung Medical
Center (IRB no. 2016-02-004). Informed consent was waived for the use
of medical data because patient information was anonymized and deiden-
tified prior to analysis.
Radiographic and microbiologic examination. The fibrocavitary
form (previously referred to as the upper lobe cavitary form) of MAC-LD
was defined by the presence of cavitary opacities and pleural thickening,
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mainly in the upper lobes, regardless of the presence of underlying chronic
obstructive lung disease in the rest of the lungs. The nodular bronchiec-
tatic form of MAC-LD was defined by the presence of multifocal bronchi-
ectasis and clusters of small nodules on chest high-resolution computed
tomography (HRCT), regardless of the presence of small cavities in the
lungs (13, 16). The HRCT images were evaluated by four of us (S.M.M.,
H.Y.P., B.W.J., and W.-J.K.), and consensus was obtained.
Sputum acid-fast bacillus (AFB) smears and cultures were obtained
using standard methods, as described previously (16). During the study
period, NTM species were identified by a PCR and restriction fragment
length polymorphism method based on the rpoB gene or by a reverse blot
hybridization assay of the rpoB gene (17–20). Drug susceptibility testing
for clarithromycin was performed using the broth microdilution method
at the Korean Institute of Tuberculosis (21). Isolates with a MIC of 32
g/ml or greater were considered resistant (21). MICs for azithromycin
were not determined, as clarithromycin is the class drug for macrolides
(21).
MAC isolates were stored at 80°C for further analyses. For the de-
tection of point mutations at position 2058 or 2059 (Escherichia coli num-
bering) in the 23S rRNA gene, PCR was performed to amplify the region
corresponding to domain V of the 23S rRNA gene, according to a method
previously described (22). The primers 23SF1 and 23SRIII were used for
PCR and sequencing (22).
Antibiotic therapy and treatment outcomes. Patients with macro-
lide-resistant MAC-LD received combination antibiotic therapy. For
most patients, the following drug dosages were used: clarithromycin,
1,000 mg/day; azithromycin, 250 mg/day; ethambutol, 15 mg/kg of body
weight/day; rifampin, 450 mg/day for a body weight of 50 kg or 600
mg/day for a body weight of50 kg; rifabutin, 300 mg/day. Streptomycin
(25 mg/kg intramuscularly two or three times a week), moxifloxacin (400
mg/day), or clofazimine (100 mg/day) was also used at the discretion of
the attending physicians.
Sputum examinations were performed 1, 3, and 6 months after initi-
ation of antibiotic treatment and then at 2- to 3-month intervals during
treatment. Sputum conversion was defined as three consecutive negative
cultures, with the time of conversion defined as the date of the first nega-
tive culture (17–19). A favorable outcome was defined as sputum culture
conversion within 12 months after initiation of treatment and mainte-
nance of a negative culture for 12 months or longer on treatment (17–19).
An unfavorable outcome was defined as no sputum culture conversion or
death. Death was attributed to MAC-LD when patients had failure of
sputum culture conversion and progression of MAC-LD at the time of
death. Patients who died after sputum culture conversion to negative, who
died of acute respiratory failure regardless of sputum culture conversion,
or who were lost to follow-up and died from unknown causes were cate-
gorized under “death due to all causes.” All dates of patient deaths were
ascertained from the medical records or the database of the National
Health Insurance Service.
Statistical analysis. All data are presented as medians and interquar-
tile ranges (IQRs) for continuous variables and as numbers and percent-
age for categorical variables. Data were compared by the Mann-Whitney
U test for continuous variables and by the Pearson 2 test or Fisher’s exact
test for categorical variables. A two-sided P value of0.05 was considered
to indicate a statistically significant difference for all analyses. All analyses
were performed with SPSS statistical software (SPSS version 23; IBM,
Armonk, NY).
RESULTS
Patient characteristics. Macrolide-resistant MAC-LD was diag-
nosed in 34 patients during the study period. The median age for
all patients was 65 years (IQR, 61 to 70 years), and the majority
(n  23 [68%]) of the patients were male. None of the patients
were infected with human immunodeficiency virus. Twenty-five
(74%) patients had a history of prior treatment of pulmonary
tuberculosis, and four (12%) had a history of previous successful
treatment of NTM lung disease caused by MAC, M. abscessus, or
M. massiliense. Chronic obstructive pulmonary disease (n  11
[32%]) and chronic pulmonary aspergillosis (n 11 [32%]) were
common comorbid diseases (Table 1).
The etiologic organisms of MAC-LD were M. intracellulare in
21 (62%) patients andM. avium in 13 (38%) patients. The sputum
AFB smear was positive in 27 (80%) patients at the time of detec-
tion of macrolide resistance. Chest radiography and HRCT were
available for all patients. Fifteen (44%) patients had the nodular
bronchiectatic form, and 19 (56%) had the fibrocavitary form of
the disease. Cavitary lesions were found by HRCT in all patients
with the fibrocavitary form and in eight patients (53%) with the
nodular bronchiectatic form. The median preoperative forced vi-
tal capacity (FVC) was 2.25 liters (IQR, 1.84 to 2.98 liters), and the
forced expiratory volume in 1 s (FEV1) was 1.96 liters (IQR, 1.36
to 2.31 liters). The patients with the fibrocavitary form had lower
FVC and FEV1 than those with the nodular bronchiectatic form
(Table 1).
Previous antibiotic therapy before the detection of macro-
lide-resistant MAC. All patients had received macrolide-based
combination treatment, and the median duration of exposure to
macrolide was 30.4 months (IQR, 20.1 to 38.7 months) before the
detection of macrolide resistance. Thirty-two patients (94%) re-
ceived clarithromycin, and two patients (6%) received azithromy-
cin followed by clarithromycin. The most common previous
treatment regimen (n  22 [65%]) consisted of macrolide, rifa-
mycin, and ethambutol, with (n 16) or without (n 6) strep-
tomycin. A combination of macrolide with another drug, exclud-
ing ethambutol, was administered to 10 patients (29%). In these
10 patients, ethambutol was discontinued due to optic neuritis
(n  9) or skin rash (n  1). One patient received the two-drug
regimen of macrolide with ethambutol. Macrolide-resistant MAC
lung disease developed in one patient after completing treatment
with combined antibiotic therapy that included oral clarithromy-
cin for M. massiliense lung disease (Table 2) (23, 24).
Treatment and outcomes after the detection of macrolide-
resistant MAC. The treatment regimens after the detection of
macrolide resistance and the treatment outcomes are summarized
in Table 3. After the detection of macrolide resistance, the macro-
lide was discontinued in 18 (53%) patients and continuously pre-
scribed in 16 (47%) patients (azithromycin in 10 patients and
clarithromycin in 6 patients). Rifamycin, as either rifampin (32
patients) or rifabutin (2 patients), was used in all patients (n 34
[100%]), and ethambutol (n  25 [74%]) was used in most pa-
tients. Moxifloxacin or clofazimine was added to the regimen for
17 (50%) and 4 (12%) patients, respectively. Streptomycin was
administered in 13 (38%) patients after the detection of macrolide
resistance and was more frequently used in patients with the fi-
brocavitary form (10/19 [53%]) than those with the nodular
bronchiectatic form (3/15 [20%]). The median duration of anti-
biotic therapy after the detection of macrolide resistance was 23.0
months (IQR, 16.8 to 45.3 months). Two (6%) patients with the
fibrocavitary form underwent surgical resection with lobectomy,
one at 3.7 months and the other at 7.7 months after the detection
of macrolide resistance.
As shown in Table 3, only five (15%) patients had favorable
outcomes, and 29 (85%) had unfavorable outcomes. The propor-
tions of patients with favorable outcomes were similar between
patients with the nodular bronchiectatic form (2/15 [13%]) and
those with the fibrocavitary form (3/19 [16%]). During the me-
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dian follow-up of 39.3 months (IQR, 22.9 to 43.4 months) after
the detection of macrolide resistance, all-cause mortality was 50%
(17/34), including mortality due to MAC-LD in nine (26%) pa-
tients. All-cause mortality was more frequent in patients with the
fibrocavitary form (13/19 [68%]) than in those with the nodular
bronchiectatic form (4/15 [27%]). The overall cumulative mor-
tality rates at 1, 3, and 5 years were 9% (n 3), 24% (n 8), and
47% (n 16), respectively.
Comparison of variables according to treatment outcomes.
There were no differences in age, sex, body mass index, etiologic
organism, radiographic type, and the presence of cavitary lesions
on HRCT according to treatment outcome. Patients with unfa-
TABLE 1 Clinical characteristics at the time of diagnosis of macrolide-resistant MAC-LD
Characteristica
Valueb
Total
Nodular
bronchiectatic
form
Fibrocavitary
form
Patients 34 (100) 15 (44) 19 (56)
Male 23 (68) 8 (53) 15 (79)
Age (yr) 65 (61–70) 65 (56–72) 66 (62–70)
BMIb (kg/m2) 19.7 (17.3–21.2) 19.5 (18.2–21.2) 19.7 (15.8–21.6)
Nonsmokers 20 (59) 10 (67) 10 (53)
Previous treatment of pulmonary TB 25 (74) 11 (73) 14 (74)
Previous treatment of NTM lung disease 4 (12) 3 (20) 1 (5)
Comorbid disease
COPD 11 (32) 3 (30) 8 (42)
Chronic pulmonary aspergillosis 11 (32) 2 (13) 9 (47)
Interstitial lung disease 2 (6) 1 (7) 1 (5)
Diabetes mellitus 4 (12) 1 (7) 3 (16)
Chronic heart disease 8 (24) 2 (13) 6 (32)
Chronic liver disease 3 (9) 2 (13) 1 (5)
Etiologic organism
M. intracellulare 21 (62) 9 (60) 12 (63)
M. avium 13 (38) 6 (40) 7 (37)
Positive sputum AFB smear 27 (80) 10 (67) 17 (90)
Cavitary lesions on chest HRCT 27 (80) 8 (53) 19 (100)
Pulmonary function testsc
FVC (liters) 2.25 (1.84–2.98) 2.90 (2.12–3.27) 2.10 (1.84–2.56)
FVC (% predicted) 63 (52–80) 81 (61–101) 56 (51–71)
FEV1 (liters) 1.96 (1.36–2.31) 2.13 (1.82–2.70) 1.77 (1.17–2.08)
FEV1 (% predicted) 77 (54–87) 85 (71–104) 65 (45–82)
a BMI, body mass index; TB, tuberculosis; COPD, chronic obstructive pulmonary disease.
b Data are presented as number (percent) or as median (interquartile range).
c Results were available for 31 patients (14 with the nodular bronchiectatic form and 17 with the fibrocavitary form).
TABLE 2 Previous treatment regimen before detection of macrolide-resistant MAC-LD
Parameter
Valuea
Total (n 34)
Nodular bronchiectatic
form (n 15)
Fibrocavitary
form (n 19)
Treatment regimen
Macrolide ethambutol rifamycin streptomycin 22 (65)b 8 (53) 14 (74)
Macrolide rifampin streptomycin or moxifloxacinc 10 (29) 5 (33) 5 (26)
Macrolide ethambutol 1 (3) 1 (7) 0 (0)
Macrolide ciprofloxacind 1 (3) 1 (7) 0 (0)
Duration of exposure to macrolide (mo) 30.4 (20.1–38.7) 30.3 (20.5–36.7) 31.7 (19.2–46.7)
a Data are presented as number (percent) or as median (interquartile range).
b Sixteen patients received streptomycin injections.
c Ethambutol was discontinued because of adverse effects, such as visual disturbance (n 9; 90%) or skin rash (n 1; 10%).
d Macrolide-resistant M. avium complex lung disease developed after completion of treatment for M. massiliense lung disease in a patient who received combined antibiotic therapy,
including oral clarithromycin.
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vorable outcomes were more likely to have sputum AFB smear
positivity at the time of detection of macrolide resistance than
those with favorable outcomes (25/29 [86%] versus 2/5 [40%];
P  0.048). Regarding treatment regimens, continued treatment
with a macrolide (P 0.648) or the addition of moxifloxacin (P
0.335), clofazimine (P 0.999), or streptomycin (P 0.999) had
no significant effect on treatment outcome. Patients who under-
went surgical resection were more likely to have a favorable out-
come (P 0.018) (Table 4).
Genetic-mutation analysis of macrolide-resistant MAC iso-
lates. Among the 34 patients with macrolide-resistant MAC-LD,
the MAC isolates of 28 (82%) patients were available for genetic-
mutation analysis. Point mutations were found at position 2058 (n
13) or 2059 (n14) of the 23S rRNA gene in all but one of the isolates
(Table 5). The most common mutation was a nucleotide change
from adenine to guanine (15/28 [53%]), followed by cytosine (10/28
[36%]) and thymine (2/28 [7%]). There was no significant difference
in mutation type according to treatment outcome (P 0.335).
DISCUSSION
This study analyzed the clinical characteristics and treatment out-
comes of 34 patients with macrolide-resistant MAC-LD, as well as
the molecular characteristics of macrolide-resistant MAC isolates.
Overall, our analyses indicate a poor prognosis for patients with
TABLE 3 Treatment modalities and outcomes after detection of macrolide-resistant MAC-LD
Parameter
Valuea
Total (n 34)
Nodular
bronchiectatic
form (n 15)
Fibrocavitary
form (n 19)
Antibiotic therapy
Macrolide 16 (47) 6 (40) 10 (53)
Rifampin or rifabutin 34 (100) 15 (100) 19 (100)
Ethambutol 25 (74) 10 (67) 15 (79)
Moxifloxacin 17 (50) 8 (53) 9 (47)
Clofazimine 4 (12) 3 (20) 1 (5)
Streptomycin 13 (38) 3 (20) 10 (53)
Surgical resection 2 (6) 0 (0) 2 (11)
Total treatment duration (mo) 23.0 (16.8–45.3) 23.9 (20.8–56.5) 22.4 (11.8–43.9)
Treatment outcome
Favorable outcome 5 (15) 2 (13) 3 (16)
Unfavorable outcome 29 (85) 13 (87) 16 (84)
Mortality
Time from detection of resistance to death (mo) 39.3 (22.9–43.4) 33.4 (24.9–41.4) 39.3 (16.6–49.8)
1-yr mortality 3 (9) 0 (0) 3 (16)
3-yr mortality 8 (24) 2 (13) 6 (32)
5-yr mortality 16 (47) 4 (27) 12 (63)
Deaths due to MAC lung disease 9 (26) 3 (20) 6 (32)
Deaths due to all causes 17 (50) 4 (27) 13 (68)
a Data are presented as number (percent) or as median (interquartile range).
TABLE 4 Comparison of variables according to treatment outcomes after diagnosis of macrolide-resistant MAC-LD
Variable
Valuea
P value
Total
(n 34 [100%])
Favorable outcome
(n 5 [15%])
Unfavorable outcome
(n 29 [85%])
Male 23 (68) 2 (40) 21 (72) 0.300
Age (yr) 65 (61–70) 65 (60–69) 65 (61–71) 0.841
BMIb (kg/m2) 19.7 (17.3–21.2) 20.4 (17.4–23.6) 19.5 (17.3–21.2) 0.363
M. intracellulare 21 (62) 3 (60) 18 (62) 0.999
Positive sputum AFB smear 27 (80) 2 (40) 25 (86) 0.048
Fibrocavitary form 16 (47) 3 (60) 16 (55) 0.999
Cavitary lesions on chest HRCT 27 (80) 4 (80) 23 (79) 0.999
Use of macrolide 16 (47) 3 (60) 13 (45) 0.648
Use of moxifloxacin 17 (50) 1 (20) 16 (55) 0.335
Use of clofazimine 4 (12) 0 (0) 4 (14) 0.999
Use of streptomycin 13 (38) 2 (40) 11 (38) 0.999
Surgical resection 2 (6) 2 (40) 0 (0) 0.018
a Data are presented as number (percent) or as median (interquartile range).
b BMI, body mass index.
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macrolide-resistant MAC-LD, with limited effective treatment
options. Five-year mortality rates, from development of resistance
to time of death, approached 50%, with the death of 26% of pa-
tients directly attributed to MAC-LD. Of the 34 patients exam-
ined, only 5 (15%) showed favorable outcomes, and there was no
statistically significant association between antibiotic regimen and
treatment outcome, although patients who underwent surgical
resection were more likely to have favorable outcomes. An AFB-
positive sputum smear at the time of detection of macrolide resis-
tance was more frequently observed in patients with unfavorable
outcomes.
During the management of patients with MAC-LD, preventing
the emergence of macrolide resistance is critical, because the de-
velopment of such resistance is strongly associated with treatment
failure and increased mortality (14, 15). The first study on mac-
rolide-resistant MAC-LD from the United States was published in
2006 and found that the major reasons (76%) for the development
of macrolide resistance were initial macrolide monotherapy and
the combination of a macrolide and a fluoroquinolone (14). That
study included patients who were previously enrolled in clinical
trials with initial macrolide monotherapy in the early 1990s (25–
27). However, a recently published study from Japan found that
macrolide monotherapy or a two-drug regimen that included a
macrolide were previously administered in only 18% and 12%,
respectively, of patients with macrolide-resistant MAC-LD (15).
The majority (60%) of patients had received adequate long-term
combination therapies prior to the emergence of macrolide resis-
tance (15).
In our study, no patient had received macrolide monotherapy
before the detection of macrolide resistance. However, approxi-
mately one-third of our patients were treated with a regimen that
did not include ethambutol because of its adverse effects. Etham-
butol is an important companion drug to prevent the emergence
of macrolide resistance (28, 29), but the adverse effects of etham-
butol, such as ocular toxicity, are a serious concern, especially in
the daily treatment for MAC-LD (30). Our study suggests that
treatment regimens without ethambutol for MAC-LD may allow
the development of macrolide resistance.
The majority (65%) of our patients received the currently rec-
ommended three oral drugs (macrolide, rifamycin, and ethambu-
tol) before the development of macrolide resistance, which is con-
sistent with a recently published study showing that 60% of
patients received the recommended combination antibiotic ther-
apy before the development of macrolide resistance (15). These
results suggest that the development of macrolide resistance can
occur even when patients are treated with multidrug treatment
regimens. The development of macrolide resistance under these
circumstances may be explained by the relatively low concentra-
tions of key drugs, including macrolides, because the concomitant
use of rifamycin often leads to reduced levels of macrolides, par-
ticularly clarithromycin, in serum (31, 32).
Another factor that may contribute to the emergence of mac-
rolide resistance during recommended treatment is a high bacte-
rial burden. In the present study, the proportion of cases with the
fibrocavitary form of MAC-LD was high (56%), and 80% of pa-
tients had smear-positive sputum specimens at the time of detec-
tion of macrolide resistance. In our institution, the proportion of
cases with the fibrocavitary form was only 19% of newly diagnosed
macrolide-susceptible MAC-LD cases (18). This high proportion
of the fibrocavitary form (53 to 76%) among cases of macrolide-
resistant MAC-LD was also reported in previous studies (14, 15).
Additionally, 79% of our patients with the fibrocavitary form were
male. It is well known that the fibrocavitary form of MAC-LD
typically affects elderly men with underlying lung disease, such as
a history of tuberculosis (13). The fibrocavitary form of MAC-LD
resembles pulmonary tuberculosis, and these patients usually had
AFB-positive sputum smears. However, it was unclear whether
these patients previously had culture-confirmed pulmonary tu-
berculosis, because patients with AFB smear-positive sputum or
those displaying chest radiographic findings suggestive of active
tuberculosis had generally been presumed to have pulmonary tu-
berculosis and were treated empirically with antituberculous
drugs in areas where tuberculosis is endemic, such as South Korea
(33).
In addition, M. intracellulare was the etiologic organism in a
higher proportion of cases in our current study (62%) than in
newly diagnosed cases of MAC-LD in our institution (45%) (18).
A previous study also found that the majority (77%) of cases of
macrolide-resistant MAC-LD were caused by M. intracellulare
(14). Some studies have found that M. intracellulare is more viru-
lent than M. avium and that patients with M. intracellulare infec-
tion are more likely to have the fibrocavitary form of MAC-LD
and more treatment failures than patients withM. avium infection
(18, 34). The high bacterial burden of a more virulent organism
could result in a greater possibility of selection for resistant organ-
isms during the treatment of MAC-LD.
With regard to treatment outcomes, the sputum conversion
rate (15%) in the present study was lower than those (26 to 36%)
reported in previous studies of macrolide-resistant MAC-LD (14,
15). The 1-year mortality rate in our study (9%) was lower than
that (25%) found in a previous study of macrolide-resistant
MAC-LD (14), although the 5-year mortality rate was significantly
higher (47%) in the present study. Moreover, the 5-year mortality
rate in patients with macrolide-resistant MAC-LD in our study
was much higher than those (13 to 26%) in patients with newly
diagnosed MAC-LD in previous studies (35–37). These time-de-
pendent increases in mortality indicate the difficulty of managing
patients with macrolide-resistant MAC-LD. Our results show that
the continuation of macrolides or the addition of moxifloxacin,
clofazimine, or streptomycin does not improve the treatment suc-
cess rate after the development of macrolide-resistant MAC-LD.
These findings were consistent with those of previous studies, al-
TABLE 5 Analysis of genetic mutations of adenines at positions 2058
and 2059 in the 23S rRNA gene of macrolide-resistant MAC clinical
isolates (n 28)
Point mutation at position 2058 or 2059a No. (%)
Presence of mutation 27 (96)
Adenine¡guanine 15 (53)
A2058G 6
A2059G 9
Adenine¡cytosine 10 (36)
A2058C 6
A2059C 4
Adenine¡thymine 2 (7)
A2058T 1
A2059T 1
Absence of mutation 1 (4)
a E. coli numbering. A, adenine; G, guanine; C, cytosine; T, thymine.
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though moxifloxacin or clofazimine can be effective for the treat-
ment of macrolide-susceptible MAC-LD (38–40). In contrast, the
combination of surgical resection and parenteral aminoglycoside
was associated with favorable treatment outcomes in the treat-
ment of macrolide-resistant MAC-LD (14), although surgical
treatment may be associated with high complication rates (41, 42).
In the present study, two patients with the fibrocavitary form who
underwent surgical resection combined with injectable medica-
tion achieved sputum-negative conversion. Although surgical re-
section can be beneficial in some patients with macrolide-resistant
MAC-LD, most patients in our study were not considered to be
candidates for surgery because of their compromised general con-
dition and destruction of lung function during the long-term pro-
gressive course of treatment prior to the detection of macrolide
resistance.
Molecular analysis of the 23S rRNA gene at positions 2058 and
2059 found high frequencies (96%) of point mutations in the
patient isolates. The mechanisms of macrolide resistance of MAC
have been studied at the molecular level, and point mutations are
well recognized to be responsible for macrolide resistance in clin-
ical isolates (43, 44). Of these point mutations, the most common
in our study was the transition from adenine to guanine, consis-
tent with the findings of a previous study (14). One study sug-
gested that, in resistant isolates, the mutation from adenine to
guanine or cytosine was associated with a high MIC, whereas a low
level of resistance was related to the mutation of adenine to thy-
mine or to the absence of point mutations at positions 2058 and
2059 (22). However, in our study, there was no difference in treat-
ment outcome according to mutation type. Point mutations at
positions 2058 and 2059 were absent from only one (4%) mac-
rolide-resistant MAC isolate in the present study. Our findings are
consistent with those of previous studies showing point mutations
at these positions in 80 to 100% of macrolide-resistant MAC iso-
lates (14, 45, 46). In isolates without point mutations at these sites,
alterations of membrane permeability and efflux pump activation
have been proposed as alternate mechanisms underlying MAC
resistance (22, 47). Additionally, although other mutations that
confer macrolide resistance in MAC have not been reported, it is
possible that such mutations do occur, either at other positions in
the 23S rRNA gene or at other genomic sites. Further molecular
analyses are needed to identify other mechanisms that contribute
to the development of macrolide resistance in MAC.
Although several of our findings are consistent with previous
reports, there are some limitations to our study. First, the investi-
gation was conducted at a single medical center, and the number
of patients was small for the detection of clinically significant find-
ings or responses to modifications in antibiotic therapy. Second,
in our study, it was not feasible to evaluate the incidence of mac-
rolide resistance in our patient population or the risk factors
for the development of macrolide resistance in patients with
MAC-LD who initiated recommended multidrug antibiotic ther-
apy because 12 (35%) patients had initiated antibiotic therapy at
other hospitals and macrolide resistance was detected at the time
they were transferred to our hospital. In addition, one patient
developed macrolide-resistant MAC-LD after antibiotic treat-
ment for M. massiliense lung disease. Previous studies from Japan
and the United States showed that macrolide resistance did not
develop even in patients with persistent positive sputum cultures
after more than 12 months of recommended multidrug antibiotic
treatment (48, 49). Our previous study found that 17% of patients
with an unfavorable microbiologic response after 12 months of
multidrug antibiotic therapy developed macrolide resistance (19).
Further studies with larger numbers of patients are needed to eval-
uate the incidence and risk factors for the development of macro-
lide resistance, as well as the efficacy of antibiotic therapy for the
treatment of macrolide-resistant MAC-LD.
In conclusion, this study found that macrolide resistance de-
veloped in the majority of patients with MAC-LD despite the ad-
ministration of recommended long-term combination therapies.
Treatment outcomes are poor and mortality is high after the de-
velopment of macrolide resistance. However, surgical resection
can be an important treatment modality in selected patients.
Overall, our analyses indicate that more effective therapy is ur-
gently needed to treat macrolide-resistant MAC-LD.
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